Monoclonal antibodies in multiple sclerosis treatment: current and future steps

Abstract

References

Adu, D. , Cockwell, P. , Ives, N.J. , Shaw, J. and Wheatley, K. (2003) Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326: 789-794.

Aggarwal, S. , Ghilardi, N. , Xie, M.H. , de Sauvage, F.J. and Gurney, A.L. (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278: 1910-1914.

Bar-Or, A. , Calabresi, P.A. , Arnold, D. , Markowitz, C. , Shafer, S. , Kasper, L.H. et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395-400.

Bielekova, B. , Catalfamo, M. , Reichert-Scrivner, S. , Packer, A. , Cerna, M. , Waldmann, T.A. et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103: 5941-5946.

Bielekova, B. , Richert, N. , Howard, T. , Blevins, G. , Markovic-Plese, S. , McCartin, J. et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101: 8705-8708.

Biogen Idec. (2009) Tysabri Update www.biogenidec.com/site/tysabri-information-center.html .

Bolt, S. , Routledge, E. , Lloyd, I. , Chatenoud, L. , Pope, H. , Gorman, S.D. et al. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties . Eur J Immunol 23: 403-411.

Boon, L. , Brok, H.P. , Bauer, J. , Ortiz-Buijsse, A. , Schellekens, M.M. , Ramdien-Murli, S. et al. (2001) Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 167: 2942-2949.

Coles, A.J. , Compston, D.A. , Selmaj, K.W. , Lake, S.L. , Moran, S. , Margolin, D.H. et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786-1801.

10.

Coles, A.J. , Cox, A. , Le, P.E. , Jones, J. , Trip, S.A. , Deans, J. et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98-108.

11.

Coles, A.J. , Wing, M.G. , Molyneux, P. , Paolillo, A. , Davie, C.M. , Hale, G. et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296-304.

12.

Ferran, C. , Dy, M. , Sheehan, K. , Schreiber, R. , Grau, G. , Bluestone, J. et al. (1991) Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur J Immunol 21: 2349-2353.

13.

Gilliland, L.K. , Walsh, L.A. , Frewin, M.R. , Wise, M.P. , Tone, M. , Hale, G. et al. (1999) Elimination of the immunogenicity of therapeutic antibodies. J Immunol 162: 3663-3671.

14.

Hartung, H.P. (2009) New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 8: 28-31.

15.

Hauser, S.L. , Waubant, E. , Arnold, D.L. , Vollmer, T. , Antel, J. , Fox, R.J. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688.

16.

Iezzi, G. , Sonderegger, I. , Ampenberger, F. , Schmitz, N. , Marsland, B.J. and Kopf, M. (2009) CD40-CD40 L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci USA 106: 876-881.

17.

Jones, P.T. , Dear, P.H. , Foote, J. , Neuberger, M.S. and Winter, G. (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525.

18.

Kawai, T. , Andrews, D. , Colvin, R.B. , Sachs, D.H. and Cosimi, A.B. (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6: 114.

19.

Kleinschmidt-DeMasters, B.K. and Tyler, K.L. (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1 a for multiple sclerosis . N Engl J Med 353: 369-374.

20.

Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.

21.

Langer-Gould, A. , Atlas, S.W. , Green, A.J. , Bollen, A.W. and Pelletier, D. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375-381.

22.

Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS / MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465.

23.

Lees, J.R. , Iwakura, Y. and Russell, J.H. (2008) Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines. J Immunol 180: 8066-8072.

24.

Lindrud, S. , Orlick, M. , Barnard, N. , Hait, W.N. and Toppmeyer, D.L. (2003) Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer. Breast J 9: 116-119.

25.

Miller, R.A. , Maloney, D.G. , Warnke, R. and Levy, R. (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306: 517-522.

26.

Mosmann, T.R. , Cherwinski, H. , Bond, M.W. , Giedlin, M.A. and Coffman, R.L. (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357.

27.

Nice (2007) Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis . NICE Technology Appraisal Guidance 127 http://www.nice.org.uk/nicemedia/pdf/TA127publicinfo.pdf.

28.

Oppmann, B. , Lesley, R. , Blom, B. , Timans, J.C. , Xu, Y. , Hunte, B. et al. (2000) Novel p19 protein engages IL-12 p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.

29.

Parish, C.R. and Liew, F.Y. (1972) Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J Exp Med 135: 298-311.

30.

Polman, C.H. , O'Connor, P.W. , Havrdova, E. , Hutchinson, M. , Kappos, L. , Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.

31.

Rose, J.W. , Burns, J.B. , Bjorklund, J. , Klein, J. , Watt, H.E. and Carlson, N.G. (2007) Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69: 785-789.

32.

Rudick, R.A. , Stuart, W.H. , Calabresi, P.A. , Confavreux, C. , Galetta, S.L. , Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.

33.

Segal, B.M. , Constantinescu, C.S. , Raychaudhuri, A. , Kim, L. , Fidelus-Gort, R. and Kasper, L.H. (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7: 796-804.

34.

Sicotte, N.L. and Voskuhl, R.R. (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57: 1885-1888.

35.

Tan, P. , Mitchell, D.A. , Buss, T.N. , Holmes, M.A. , Anasetti, C. and Foote, J. (2002) `Superhumanized' antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol 169: 1119-1125.

36.

't Hart, B.A. , Blezer, E.L. , Brok, H.P. , Boon, L. , de, B.M. , Bauer, J. et al. (2005) Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. J Neuroimmunol 163: 31-39.

37.

Trapp, B.D. , Peterson, J. , Ransohoff, R.M. , Rudick, R. , Mork, S. and Bo, L. (1998) Axonal transection in the lesions of multiple sclerosis . N Engl J Med 338: 278-285.

38.

US Food and Drug Administration (2009) Natalizumab (marketed as Tysabri) Information. http://www.fda.gov/Cder/drug/infopage/natalizumab/default.htm.

39.

Van, A.G. , Van, R.M. , Sciot, R. , Dubois, B. , Vermeire, S. , Noman, M. et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368.